Advani, R., Bartlett, N., Smith, S., Roschewski, M., Popplewell, L., Flinn, I., Collins, G., Ghosh, N., LaCasce, A., Asch, A., Kline, J., Kesevan, M., Tran, T., Lynn, J., Huang, J., Agoram, B., Volkmer, J., Takimoto, C., Chao, M., & Mehta, A. (n.d.). tHE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS. Hematological oncology, 37, 89–90. http://access.bl.uk/ark:/81055/vdc_100086210627.0x000041